Larvol Delta - BGB9002001IIT-A-Phase-II-Study-to-Explore-the-Safety-Tolerability-and-Preliminary-Antitumor-Activity-of-Sitravatinib-Plus-Tislelizumab-or-Combination-With-Nabpaclitaxel-in-Patients-With-Locally-Recurrent-or-Metastatic-Triple-Negative-Breast-Cancer-TNBC

albumin-bound paclitaxel - Generic mfg.

sitravatinib (MGCD516) - BeOne Medicines

Tevimbra (tislelizumab-jsgr) - BeOne Medicines

http://clinicaltrials.gov/ct2/show/NCT04734262

Sep 22, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next